[{"address1": "60 Leveroni Court", "city": "Novato", "state": "CA", "zip": "94949", "country": "United States", "phone": "415 483 8800", "website": "https://www.ultragenyx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.", "fullTimeEmployees": 1294, "companyOfficers": [{"maxAge": 1, "name": "Dr. Emil D. Kakkis M.D., Ph.D.", "age": 65, "title": "Founder, President, CEO & Director", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 1627576, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Howard  Horn", "age": 46, "title": "Executive VP of Corporate Strategy & CFO", "yearBorn": 1979, "fiscalYear": 2024, "totalPay": 947770, "exercisedValue": 0, "unexercisedValue": 261805}, {"maxAge": 1, "name": "Mr. John Richard Pinion II", "age": 59, "title": "Chief Quality Operations Officer & Executive VP of Translational Sciences", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 923934, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Erik  Harris M.B.A.", "age": 55, "title": "Executive VP & Chief Commercial Officer", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 985266, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Eric  Crombez M.D.", "age": 52, "title": "Chief Medical Officer & Executive VP", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 987676, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Theodore A. Huizenga", "age": 54, "title": "Senior VP, Corporate Controller & Principal Accounting Officer", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karah Herdman Parschauer J.D.", "age": 47, "title": "Chief Legal Officer & Executive VP of Corporate Affairs", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 846744, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ernie W. Meyer", "age": 60, "title": "Chief Human Resources Officer & Executive VP", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Vimal  Srivastava", "age": 60, "title": "Senior Vice President of Business Development & Alliance Management", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Dennis Karl Huang", "age": 60, "title": "Chief Technical Operations Officer and Executive VP of Gene Therapy Operations", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 331330, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 2, "compensationRisk": 10, "shareHolderRightsRisk": 7, "overallRisk": 8, "governanceEpochDate": 1767225600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 23.0, "open": 22.84, "dayLow": 22.5, "dayHigh": 24.0, "regularMarketPreviousClose": 23.0, "regularMarketOpen": 22.84, "regularMarketDayLow": 22.5, "regularMarketDayHigh": 24.0, "payoutRatio": 0.0, "beta": 0.162, "forwardPE": -5.641439, "volume": 3609470, "regularMarketVolume": 3609470, "averageVolume": 1957756, "averageVolume10days": 4856980, "averageDailyVolume10Day": 4856980, "bid": 31.49, "ask": 35.72, "bidSize": 2, "askSize": 2, "marketCap": 2276870656, "fiftyTwoWeekLow": 18.41, "fiftyTwoWeekHigh": 46.5, "allTimeHigh": 179.647, "allTimeLow": 18.41, "priceToSalesTrailing12Months": 3.6106532, "fiftyDayAverage": 32.9979, "twoHundredDayAverage": 33.1472, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 2717651968, "profitMargins": -0.91949, "floatShares": 92894391, "sharesOutstanding": 96477569, "sharesShort": 8600577, "sharesShortPriorMonth": 7828953, "sharesShortPreviousMonthDate": 1763078400, "dateShortInterest": 1765756800, "sharesPercentSharesOut": 0.089099996, "heldPercentInsiders": 0.03122, "heldPercentInstitutions": 1.04099, "shortRatio": 6.09, "shortPercentOfFloat": 0.0923, "impliedSharesOutstanding": 96477569, "bookValue": 0.095, "priceToBook": 248.42107, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -579828992, "trailingEps": -5.93, "forwardEps": -4.18333, "enterpriseToRevenue": 4.31, "enterpriseToEbitda": -5.342, "52WeekChange": -0.44678855, "SandP52WeekChange": 0.14778805, "quoteType": "EQUITY", "currentPrice": 23.6, "targetHighPrice": 128.0, "targetLowPrice": 23.0, "targetMeanPrice": 69.65, "targetMedianPrice": 70.0, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 20, "totalCash": 425248000, "totalCashPerShare": 4.416, "ebitda": -508700992, "totalDebt": 863113024, "quickRatio": 1.593, "currentRatio": 1.892, "totalRevenue": 630598016, "debtToEquity": 5341.376, "revenuePerShare": 6.463, "returnOnAssets": -0.24919, "returnOnEquity": -3.13433, "grossProfits": -163816000, "freeCashflow": -195176992, "operatingCashflow": -445673984, "revenueGrowth": 0.147, "grossMargins": -0.25978002, "ebitdaMargins": -0.8067, "operatingMargins": -1.0685099, "financialCurrency": "USD", "symbol": "RARE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Ultragenyx Pharmaceutical Inc.", "longName": "Ultragenyx Pharmaceutical Inc.", "corporateActions": [], "postMarketTime": 1767398608, "regularMarketTime": 1767387600, "exchange": "NMS", "messageBoardId": "finmb_117471985", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1391178600000, "regularMarketChangePercent": 2.6087, "regularMarketPrice": 23.6, "fiftyTwoWeekLowChange": 5.1900005, "fiftyTwoWeekLowChangePercent": 0.28191203, "fiftyTwoWeekRange": "18.41 - 46.5", "fiftyTwoWeekHighChange": -22.9, "fiftyTwoWeekHighChangePercent": -0.4924731, "fiftyTwoWeekChangePercent": -44.678856, "earningsTimestamp": 1762290000, "earningsTimestampStart": 1762290000, "earningsTimestampEnd": 1762290000, "earningsCallTimestampStart": 1762293600, "earningsCallTimestampEnd": 1762293600, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -5.93, "epsForward": -4.18333, "epsCurrentYear": -5.77545, "priceEpsCurrentYear": -4.0862617, "fiftyDayAverageChange": -9.397898, "fiftyDayAverageChangePercent": -0.2848029, "twoHundredDayAverageChange": -9.547201, "twoHundredDayAverageChangePercent": -0.28802434, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "marketState": "CLOSED", "postMarketChangePercent": -1.4830525, "postMarketPrice": 23.25, "postMarketChange": -0.35000038, "regularMarketChange": 0.6, "regularMarketDayRange": "22.5 - 24.0", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1957756, "displayName": "Ultragenyx Pharmaceutical", "trailingPegRatio": null, "__fetch_time": "2026-01-03"}]